1655 Roberts Boulevard, NW
888-427-9654 CUSTOMER SERVICE
Founded in 1984, CryoLife was the first biomedical company in the world to commercialize the low temperature preservation of human implantable tissues for complex cardiac and vascular reconstruction. Today, in addition to our ongoing advancements in tissue preservation, the company pioneers research in the development of implantable biological devices, surgical adhesives, hemostatic agents, and biomaterials for use in cardiac, vascular, and general surgery.
CryoLife's patented decellurization technology serves as the foundation for the next generation in tissue processing. The SynerGraft technology, developed and patented by CryoLife, is designed to remove cells and cellular remnants from tissues without compromising the integrity of the underlying collagen matrix. CryoLife currently offers CryoValve SG Pulmonary Human Heart Valve and CryoPatch SG processed through the SynerGraft process.